Paushak
BSE: PAUSHAKLTD · Specialty Chemicals
Snapshot
Unlock Paushak's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Paushak Ltd. is a specialty chemicals company specialising in the development and manufacturing of phosgene-based derivatives. Its product portfolio includes chloroformates, isocyanates, carbonates, and chlorides, serving various industrial applications.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the production and sale of complex chemical intermediates, leveraging its expertise in phosgene chemistry. It operates as a key supplier for downstream industries requiring specialised chemical building blocks.
Growth Outlook
Growth is driven by the increasing demand for phosgene-based intermediates in the pharmaceutical and agrochemical sectors. The company continues to focus on process optimisation and expanding its specialised product range.
Key Risks
- Regulatory and Environmental Compliance. As a manufacturer of hazardous phosgene-based chemicals, the company faces stringent environmental regulations and safety standards.
- Raw Material Price Volatility. Fluctuations in the prices of key chemical feedstocks can significantly impact operating margins.
- Operational Hazards. The handling of highly toxic phosgene gas presents inherent operational risks that require rigorous safety protocols and infrastructure maintenance.
- Geopolitical and Export Risks. Exposure to international markets subjects the company to risks associated with global supply chain disruptions and trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Paushak and 5,000+ companies — free.
Key Metrics
REVENUE
₹277 Cr
TTM · standalone
NET PROFIT
₹47 Cr
TTM · standalone
EPS
₹19.18
TTM · standalone
RETURN ON EQUITY
9.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.9%
TTM · standalone
P/E
31.6×
Q2 FY27 · standalone
EV/EBITDA
16.5x
Q2 FY27 · standalone
EBITDA MARGIN
34.1%
TTM · standalone
NET PROFIT MARGIN
15.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.2%
Q2 FY27 · standalone
Peers · Specialty Chemicals
| Company | Mkt Cap | P/E (TTM) | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
PaushakPAUSHAKLTD | ₹1,495 Cr | 31.6× | 16.50 | 28.0% | 34.1% | 9.5% | 10.9% | -17.7% |
IndokemINDOKEM | ₹1,756 Cr | 777.2× | 211.61 | -4.5% | 4.8% | 3.5% | 6.7% | -9.1% |
Camlin Fine Sciences LimitedCAMLINFINE | ₹1,699 Cr | 327.7× | 19.03 | 8.4% | 6.4% | 0.1% | 0.5% | -54.8% |
Titan BiotechTITANBIO | ₹1,682 Cr | 13.6× | 34.46 | 36.9% | 22.3% | 20.2% | 25.3% | -69.1% |
Nitta Gelatin India LimitedNITTAGELA | ₹1,591 Cr | 15.4× | 10.05 | 10.0% | 26.6% | 22.1% | 29.4% | +95.4% |
Vidhi Specialty Food Ingredients LimitedVIDHIING | ₹1,535 Cr | 25.5× | 16.92 | 34.8% | 18.7% | 17.9% | 24.5% | -9.1% |
As of Q2 FY27
Financials
Paushak
BSE: PAUSHAKLTD · Specialty Chemicals
Snapshot
Unlock Paushak's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Paushak Ltd. is a specialty chemicals company specialising in the development and manufacturing of phosgene-based derivatives. Its product portfolio includes chloroformates, isocyanates, carbonates, and chlorides, serving various industrial applications.
Geography mix
- NaN%
- NaN%
Business Model
The company generates revenue through the production and sale of complex chemical intermediates, leveraging its expertise in phosgene chemistry. It operates as a key supplier for downstream industries requiring specialised chemical building blocks.
Growth Outlook
Growth is driven by the increasing demand for phosgene-based intermediates in the pharmaceutical and agrochemical sectors. The company continues to focus on process optimisation and expanding its specialised product range.
Key Risks
- Regulatory and Environmental Compliance. As a manufacturer of hazardous phosgene-based chemicals, the company faces stringent environmental regulations and safety standards.
- Raw Material Price Volatility. Fluctuations in the prices of key chemical feedstocks can significantly impact operating margins.
- Operational Hazards. The handling of highly toxic phosgene gas presents inherent operational risks that require rigorous safety protocols and infrastructure maintenance.
- Geopolitical and Export Risks. Exposure to international markets subjects the company to risks associated with global supply chain disruptions and trade policy changes.
Start your research today
Unlock AI insights, financials, peers and live data on Paushak and 5,000+ companies — free.
Key Metrics
REVENUE
₹277 Cr
TTM · standalone
NET PROFIT
₹47 Cr
TTM · standalone
EPS
₹19.18
TTM · standalone
RETURN ON EQUITY
9.5%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
10.9%
TTM · standalone
P/E
31.6x
Q2 FY27 · standalone
EV/EBITDA
16.5x
Q2 FY27 · standalone
EBITDA MARGIN
34.1%
TTM · standalone
NET PROFIT MARGIN
15.1%
Q2 FY27 · standalone
DEBT TO EQUITY
0.2%
Q2 FY27 · standalone
Peers · Specialty Chemicals
As of Q2 FY27